Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We are reaffirming our Outperform recommendation on Eastman Chemical Company (EMN - Analyst Report). We believe that the company is well placed to benefit in the second half of 2012 from the synergies of Solutia acquisition.
Adjusted earnings of $1.40 a share for second-quarter 2012 topped the Zacks Consensus Estimate by 6 cents. Revenues, however, dipped 2% year over year to $1,853 million, and missed the Zacks Consensus Estimate of $1,948 million.
Eastman Chemical witnessed weakness across the board in the quarter with its Specialty Plastics division, in particular, was hit by weak demand. The company nevertheless continues to expect double-digit earnings growth in 2012.
Eastman Chemical’s diversified chemical portfolio, along with its integrated and diverse downstream businesses, is driving earnings. The company also benefits from business restructuring and cost-cutting measures.
Eastman Chemical, in July 2012, completed its acquisition of Solutia Inc., a global leader in performance materials and specialty chemicals, in a cash and stock deal worth roughly $4.8 billion (including assumption of Solutia’s debt). The acquisition represents a major step in the company’s strategy to boost its foothold in the emerging markets.
Especially, the Solutia acquisition should significantly accelerate Eastman Chemical’s growth efforts and offer lucrative opportunities in Asia Pacific. The company expects compound annual growth rate in Asia Pacific to approach 10% over the next several years.
It expects meaningful revenue synergies by leveraging technology and business capabilities and overlapping end-markets (especially automotive and architecture) of both companies.
Increased capacity additions should also support Eastman Chemical’s results in 2012. The company’s non-phthalate plasticizer manufacturing facility in Texas City will produce “Eastman 168” non-phthalate plasticizer, increasing its capacity by roughly 60%. With the capacity expansion, Eastman Chemical will be able to serve the growing needs of non-phthalate plasticizers globally.
Eastman Chemical is also making progress in its growth initiatives through its joint venture in China for a 30,000-ton acetate tow manufacturing facility, which is expected to come online in mid-2013.
Moreover, the company recently entered into a joint venture with Sinopec Yangzi Petrochemical Company Limited to build a hydrogenated hydrocarbon resin plant in Nanjing, China. The facility will expand Eastman Chemical’s total capacity for hydrogenated resins by 50%, making it the largest supplier of hydrogenated hydrocarbon resins globally.
Eastman Chemical, which competes with The Dow Chemical Company (DOW - Analyst Report), EI DuPont de Nemours and Company (DD - Analyst Report) and Celanese Corporation (CE - Analyst Report), currently retains a short-term Zacks #2 Rank (Buy).
Get the full Analyst Report on EMN - FREE
Get the full Analyst Report on DD - FREE
Get the full Analyst Report on DOW - FREE
Get the full Analyst Report on CE - FREE